silence.. |
|
| Keith AlcornPublished: 28 May 2013 France led the world in the proportion of its hepatitis C patients who received treatment in 2010, but some countries in southern and eastern Europe had treatment rates that were almost tenfold lower, according to research presented last month at the International Liver Congress in Amsterdam. However, European epidemiologists and physicians cautioned that the results should be treated as indicative rather than hard estimates, and that far more research is needed into hepatitis C prevalence in order to arrive at reliable estimates of treatment need in the European region. The study, carried out by the Center for Disease Analysis in Colorado, USA, sought to develop estimates of the number of people who received treatment with pegylated interferon and ribavirin in 2010. This was the last year in which all European countries had access to a comparable regimen for the treatment of hepatitis C. In 2011, the HCV protease inhibitors telaprevir ("Incivo") and boceprevir ("Victrelis") began to become available in some European countries following European marketing approval. continua a leggere qui www.aidsmap.com/page/2663697/ |
| | |
